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Abstract
This study is aimed to clarify the association between MDMA cumulative use and cognitive dysfunction, and the potential
role of candidate genetic polymorphisms in explaining individual differences in the cognitive effects of MDMA. Gene
polymorphisms related to reduced serotonin function, poor competency of executive control and memory consolidation
systems, and high enzymatic activity linked to bioactivation of MDMA to neurotoxic metabolites may contribute to explain
variations in the cognitive impact of MDMA across regular users of this drug. Sixty ecstasy polydrug users, 110 cannabis
users and 93 non-drug users were assessed using cognitive measures of Verbal Memory (California Verbal Learning Test,
CVLT), Visual Memory (Rey-Osterrieth Complex Figure Test, ROCFT), Semantic Fluency, and Perceptual Attention (Symbol
Digit Modalities Test, SDMT). Participants were also genotyped for polymorphisms within the 5HTT, 5HTR2A, COMT, CYP2D6,
BDNF, and GRIN2B genes using polymerase chain reaction and TaqMan polymerase assays. Lifetime cumulative MDMA use
was significantly associated with poorer performance on visuospatial memory and perceptual attention. Heavy MDMA users
(.100 tablets lifetime use) interacted with candidate gene polymorphisms in explaining individual differences in cognitive
performance between MDMA users and controls. MDMA users carrying COMT val/val and SERT s/s had poorer performance
than paired controls on visuospatial attention and memory, and MDMA users with CYP2D6 ultra-rapid metabolizers
performed worse than controls on semantic fluency. Both MDMA lifetime use and gene-related individual differences
influence cognitive dysfunction in ecstasy users.
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Introduction
3,4-methylenedioxymethamphetamine (MDMA, ecstasy) is one
of the most popular illegal psychostimulants abused among youth.
There is compelling evidence that MDMA produces selective
long-lasting serotonergic neuroadaptations, including regulatory
changes in the expression of the serotonin transporter [1–3]. In
humans, ligand-binding imaging studies have reported decreased
serotonin transporter (SERT) binding throughout the cerebral
cortices and the hippocampus in MDMA users compared to
healthy controls [4,5]. Furthermore, these studies have shown that
decreased SERT binding is associated with lower memory
performance in MDMA users. Although some studies have
observed MDMA abstinence-related recovery of SERT availabil-
ity in the midbrain and thalamus [6,7] there is no data about
SERT recovery in the cortex, and post-mortem evidence indicates
that cortical SERT protein reductions can be more robust and
durable than indicated by neuroimaging studies [8]. Overall these
findings are suggestive of MDMA-induced neurotoxicity, which
primarily affects the serotonin system and is linked to memory
dysfunction.
Despite these findings about serotonin neuroadaptations, there
is still debate on the question if MDMA use is reliably associated
with neuropsychological impairment, regardless of the effects of
concomitant use of other substances (e.g., cannabis, alcohol or
other stimulants). Literature on this topic is characterized by
considerable heterogeneity of results, which is attributable to the
large amount of confounders inherent to research on the
deleterious effects of MDMA [9]. Two meta-analyses of
neuropsychological studies in MDMA users have concluded that
MDMA use is robustly associated with learning and memory
impairments [10,11]. This conclusion is substantiated by evidence
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from studies showing dose-related detrimental effects of MDMA
use on learning and memory [12–14]. Nonetheless, the size of
these dose-related effects is modest (6–11% of explained variance
[13], suggesting that other relevant individual differences, may
play an important role in MDMA-induced neuropsychological
deficits.
A number of genes affecting serotonin function, including SERT
and 5HT2A receptor gene polymorphisms, have demonstrated
significant associations with cognition and may therefore impor-
tantly impact MDMA use related neuropsychological effects [15].
In addition, gene variants involved in MDMA pharmacodynamics
and putative neurotoxic mechanisms, such as COMT [16,17] and
CYP2D6 polymorphisms [18], and those impacting neural
signaling pathways involved in learning and memory (e.g., BDNF
and glutamate genes) [19–21] may also contribute to explain
MDMA-induced neuropsychological deficits in humans [22].
Some of the dopamine and serotonin gene polymorphisms are
equally relevant for MDMA-related cognitive effects based on
their well-recognized role in modulating prefrontal cortex
functioning and executive control [23,24]. There is growing
evidence that memory decrements in MDMA users are more
neatly observable when neuropsychological probes involve a
greater degree of complexity in terms of organization demands
[25,26]. These findings suggest that executive control processes
linked to prefrontal systems may be impacted by the use of
MDMA, and that genetic differences related to these systems may
likely mediate these effects. In summary, different gene polymor-
phisms related to reduced serotonin function (SERT s/s and
5HT2a Tyr genotypes), high enzymatic activity linked to the
bioactivation of MDMA to neurotoxic metabolites (COMT val/val
and CYP2D6 ultra-rapid metabolizers), and poor competency of
executive control and memory consolidation systems (COMT val/
val, BDNF met/met, and GRIN2B C/C) can contribute to explain
variations in the cognitive impact of MDMA across regular users
of this drug.
This study seeks to clarify the association between MDMA
cumulative use and cognitive dysfunction, and the potential role of
a number of relevant genetic polymorphisms in explaining
individual differences in the cognitive effects of MDMA. To reach
this aim, we examined cognitive performance in a sample of
MDMA users recruited from a homogeneous socio-demographic
context and thoroughly assessed to rule out psychiatric comor-
bidities. The sample also includes considerable variability in
MDMA use patterns, which allowed us to characterize dose-
related effects of cumulative MDMA use on cognitive perfor-
mance. Neuropsychological testing was focused on those cognitive
domains that have been consistently linked to MDMA use across
studies: verbal and visual memory, attention/processing speed and
executive functions. We hypothesize: (i) that heavier MDMA use
would correlate with poorer neuropsychological performance in a
dose-dependent fashion; (ii) that heavy MDMA users would
perform poorer than cannabis and healthy comparison individuals
on neuropsychological tests of processing speed, memory and
fluency (indicating robust effects of MDMA on cognition
regardless of co-abuse of cannabis); and (iii) that MDMA use
would exacerbate cognitive performance decrements in individuals
carrying genotypes associated with lower functionality of the
serotonin, glutamate and dopamine systems.
Methods and Materials
Participants
Two hundred sixty-three Caucasian participants were recruited,
of whom 60 were MDMA polydrug users, 110 were cannabis users
and 93 were non-users. MDMA users were further classified into
two subgroups according to their lifetime MDMA use applying a
cut-off of 100 tablets (more than 100 tablets defined as heavy users)
[27]. Volunteers were recruited through several sources: ‘word of
mouth’, advertisement in the local university, and advertisement in
the website of a local NGO (Energy Control) specialized in
providing harm reduction guidelines among drug users. Potential
participants were medically screened in the clinical research unit
to rule out the presence of physical or neurological illness –as
determined by standard physical examinations and biochemical
determinations (supervised by the medical director –MFA). They
were also carefully assessed to diagnose possible comorbid
psychopathological disorders using a well-validated psychiatric
interview –the Psychiatric Research Interview for Substance and
Mental Disorders (PRISM; [28]) –which outcomes were super-
vised by two expert psychiatrists (MTM and RMS). Potential
participants having medical illnesses or comorbid psychiatric
disorders were excluded from the study. In addition, the PRISM
interview also provides diagnoses for the whole spectrum of
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
substance use disorders, such that we were able to rule out
potential participants meeting criteria for abuse or dependence on
drugs different than the ones targeted as the main aim of this study
(MDMA and cannabis). Specifically, the following exclusion
criteria were applied taking into account the data collected during
the interview: for cannabis users, current history of regular use of
other illegal drugs during last year, and past use of other illegal
drugs for more than 5 occasions during lifetime; for non-users,
current history of use of any illegal drugs during the past year, and
past use of any illegal drugs in more than 5 occasions. Alcohol and
nicotine use (but not abuse or dependence) was permitted. As for
the MDMA group, because it was impossible to recruit exclusive
MDMA users, we included MDMA users with exposure to other
drugs if they did not meet abuse or dependence criteria for these
other drugs.
Test procedure
This study was approved by and conducted in accordance with
the local ethics committee (CEIC-IMAS). Upon arrival to the
research centre (IMIM, Hospital del Mar Research Institute),
participants were informed of the ensuing protocol and provided
informed consent before participating in the study.
All participants were subjected to an initial exploration that
included a detailed medical history, biochemical analyses,
physical examination, urine and hair toxicology screens, and a
brief neurological examination. They were also assessed with a
structured psychiatric interview specifically designed to diagnose
lifetime use of different drugs and psychiatric comorbidity among
substance users (PRISM [28]) administered by a psychiatrist or a
clinical psychologist. Toxicology history in the past six months
was confirmed by hair testing [29,30]. All participants were
requested to observe a 72 h abstinence period, and urine and hair
drug screens were carried out by immunoassay (CEDIA,
Thermo-Fisher) to confirm abstinence. Drug classes screened
for included: cannabis, MDMA, cocaine and amphetamine/
methamphetamine. A positive urine drug test excluded the
participant for further assessments. This procedure allowed us to
reliably classify participants into the different subgroups accord-
ing to their pattern of drug use. All participants meeting inclusion
criteria underwent a neuropsychological assessment session of
180 minutes, although here we only report analyses from a subset
of these measures. All subjects were economically compensated
for their participation.
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Cognitive measures
We administered the Vocabulary test from the WAIS-III
(estimated IQ) [31], the California Verbal Learning Test (CVLT
II) (verbal memory) [32], the Rey-Osterrieth Complex Figure Test
(ROCFT) (visual spatial organization –Copy, and memory –
Recall) [33], the Symbol Digit Modalities Test (attention/
processing speed) [34], and the Category Word Fluency test
[35]. A more detailed description of these tests can be found in
[36].
Genotyping
Genomic DNA was extracted from the peripheral blood
leukocytes of all the participants using Flexi Gene DNA kit
(Qiagen Iberia, S.L., Spain) according to the manufacturer’s
instructions.
5HTTLPR genotyping was performed using polymerase chain
reaction (PCR) as described in [37]. The 5HTTLPR (A/G)
polymorphism (rs25531) was detected by MspI restriction enzyme
digestion [38] with minor modifications. Briefly, 1 ml of the
5HTTLPR PCR was digested in a 10 ml reaction assay containing
16 NEBuffer 2 and 3 U MspI at 37uC for 3 h and a final
inactivation step of 20 minutes at 65uC. The resulting fragments
were detected on an automatic ABI 3730XL capillary sequencer
and analyzed by GeneMapper Software v3.5 (Applied Biosystems).
Product sizes for the digest were: long A (LA) = 337 bp, short A
(SA) = 292 bp, long G (LG) = 162 bp, and short G (Sg) = 162 bp.
In some cases, were MspI digestion gave unclear results the
samples were sequenced to assign the correct genotype. Sequenc-
ing was performed in both, the sense and antisense orientations.
The excess primers and deoxynucleotides in the polymerase chain
reaction (PCR) products were then degraded by adding a 2 ml of a
solution of 0.8 units of shrimp alkaline phosphatase (New England
Biolabs, Ipswich, MA), 4 units of Escherichia coli Exonuclease I (New
England Biolabs) and 0.646 shrimp alkaline phosphatase buffer.
The mixture was incubated at 37uC for 15 min, followed by
deactivation for 15 min at 80uC. Sequencing reactions were
performed with BigDye v3.1 (Applied Biosystems) in 10 ml total
volume containing 1 ml template (approximately 25 ng), 3.2 pmol
primer, 1 ml Applied Biosystems 56DNA sequencing buffer, 2 ml
BigDye v3.1, and water. The reactions were cycled at 94uC for
3 min, followed by 30 cycles at 96uC for 10 sec, 50uC for 5 sec,
and 60uC for 4 min. Reactions were then purified with PureLink
Quick Gel extraction kit (Invitrogen) according to manufacturer’s
instructions. Samples were analyzed on a Prism 3730xl DNA
Analyzer (Applied Biosystems).
The COMT val108/158met (rs4680) and BDNF val66met (rs6265)
single nucleotide polymorphism (SNP) allelic variants were
determined using the 59 exonuclease TaqMan assay with ABI
7900HT Sequence Detection System (Real Time PCR) supplied
by Applied Biosystems. Primers and fluorescent probes were
obtained from Applied Biosystems (TaqMan SNP Genotyping
assays: assay ID C_2255335_10 and C_11592758_10 for rs4680
and rs6265, respectively). Reaction conditions were those
described in the ABI PRISM 7900HT user’s guide. Endpoint
fluorescent signals were detected on the ABI 7900, and the data
were analyzed using SDS software, version 2.3 (Applied
Biosystems).
The CYP2D6, GRIN2B C2664T (rs1806201), the 5HT2A
His452Tyr (rs6314) and T102C (rs6313) genotypes were performed
using the PHARMAchipTM DNA array (Progenika Biopharma,
Derio, Spain) [39]. This DNA microarray allows the screening of
genetic variants for phase I and phase II drug metabolism enzymes
(DME), drug transporters, and drug protein effectors based on
allele-specific oligonucleotide hybridization (ASO).
Statistical Analyses
Sample characteristics, including drug consumption, are de-
scribed by means of either mean and standard deviation (numerical
variables) or absolute and relative frequencies (categorical variables).
To quantify differences among the three groups, a generalization of
Cohen’s d, the standard mean difference for more than two groups,
was computed. Following the suggestions of Cohen, values of 0.25
and 0.4 indicate medium and large effect sizes, respectively [40].
The chi-square test was applied to study the association between
drug consumption (ecstasy consumption, cannabis consumption or
control group) and each of the genotypes studied. In addition, it was
used to check whether the Hardy-Weinberg equilibrium holds
among each of the three populations under study. At a univariate
level, the correlation between the cognitive performance and both
lifetime ecstasy and lifetime cannabis consumption was quantified
by Pearson’s correlation coefficient among those individuals
consuming ecstasy and those consuming cannabis, respectively.
Lifetime consumption was measured in number of tablets (ecstasy)
and number of joints (cannabis), respectively. These correlation
coefficients were also computed for the subgroups defined by the
COMT val158met genotype, on one hand, and the 5HTTLPR
genotype, on the other. Since several significant correlations with
the neuropsychological variables were found (as described in the
following section), in the sequel, a distinction was made between
regular and heavy ecstasy users taking the consumption of 100
ecstasy pills during lifetime as cutoff. Since the principal interest was
to study the association between cognitive performance and both
drug consumption and each of the genotypes of interest, ANCOVA
models were fitted for all neuropsychological variables and each
genotype separately. These models included drug consumption
group and the respective genotype as predictive variables of interest
as well as gender and the WAIS-III Vocabulary index score; the
Vocabulary index was used as a proxy of cultural level and verbal
IQ. These two variables, sex and WAIS-III Vocabulary index, were
included in all ANCOVA models in order to rule out the possible
confusion due to differences observed among the drug consumption
groups with respect to sex and education/IQ. Initially, all models
did also include the two-way interaction between genotype and drug
consumption. Whenever the interaction could be discarded, both
factors were studied separately using the ANCOVA model
excluding interaction. If a significant effect was observed of either
factor, post-hoc multiple comparisons were carried out in the
framework of the corresponding model using the Tukey test. If, by
contrast, the interaction was significant, the effect of drug
consumption was studied separately for each genotype expression
and, vice versa. Again, the Tukey test for multiple comparisons was
applied for these analyses in the framework of the ANCOVA
models including interaction.
Statistical significance was set at 0.05 for the two-way genotype-
drug consumption interaction within all ANCOVA models in
order to reduce the probability of a possible Type II error. For
those variables showing a significant interaction effect, results from
follow-up pairwise comparisons were thresholded at p,= 0.01 to
protect against Type I error was applied. The statistical software
package R (The R Foundation for Statistical Computing), version
2.11.1, was used for all analyses. In particular, R Package
multcomp [41] was used for the multiple pairwise comparisons.
Results
Sample characteristics
Socio-demographic variables, drug use characteristics and
genotype distributions are presented in Table 1. Largest standard-
ized mean differences (SMD) among the three samples were
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observed with respect to smoking habits (SMD = 0.69) and age of
first alcohol use (SMD = 0.48). In addition, the groups differed
notably in terms of the WAIS-III score (SMD = 0.3) and age
(SMD = 0.25) with highest values among controls (average WAIS-III
score of 12.6) and MDMA users (23.2 years), respectively. Despite
the differences observed, neither age nor smoking or age of first
alcohol consumption were included in the regression models. These
characteristics were not considered possible confounders because of
the relatively small interquartile range of age (20–24 years) and the
lack of correlation of the other two variables with the neuropsycho-
logical variables under study (results not shown), respectively.
Genotype distributions
Genotype distributions by group are presented in Table 2. The
tests of Hardy-Weinberg equilibrium among the three different
groups showed equilibrium for all genotypes except for the COMT
val158met polymorphism in the cannabis group (p,0.01).
No significant differences were observed in the genotype
distributions among the different groups, except for the 5HTTLPR
and the COMT val158met polymorphisms. Significant differences
were observed regarding the genotype distributions for the COMT
val158met polymorphism (p,0.05) when the distinction between
heavy and light MDMA users was taken into account. There were
a higher number of individuals with the val/val genotype in the
heavy MDMA users group (42.9%) compared to the control group
(29.0%). The val/met genotype was also overrepresented in the
cannabis group (63.6%) compared to the control group (48.4%)
(p,0.05).
Correlations between neuropsychological variables and
MDMA/cannabis lifetime consumption
MDMA lifetime use showed a significant negative association with
ROCFT Copy Accuracy (r =20.604, IC95%: [20.744, 20.413]),
Immediate Recall (r =20.391, IC95%: [20.587, 20.152]), and
Delayed Recall (r =20.464, IC95%: [20.642, 20.238]). MDMA
lifetime use was also significantly correlated with SDMT
(r =20.269, IC95%: [20.489, 20.016]). No other correlations
reached statistical significance.
Neuropsychological performance by group and
genotype analyses
Results are presented in tables 3 and 4.
Verbal Memory (CVLT)
We found no effects of group, genotype or the group x genotype
interaction on performance indices from this test.
Visual Memory (ROFCT)
Copy Accuracy. We found a main group effect; paired
contrasts indicated that heavy MDMA users had lower scores than
Table 1. Demographic variables, drug consumption characteristics.
MDMA (n=60) Cannabis (n=110) Control (n= 93)
n (%) n (%) n (%) SMDc
Agea 23.2 (3.2) 21.6 (2.7) 22.8 (4.1) 0.25
Vocabulary WAIS-IIIa 11.4 (2.4) 11.5 (2.1) 12.6 (2.0) 0.30
Gender
Male 33 (55.0) 69 (68.2) 49 (52.7) 0.11
Female 27 (45.0) 41 (37.3) 44 (47.3)
University Degreeb
Yes 41 (68.3) 75 (68.2) 83 (90.2) 0.30
No 19 (31.7) 35 (31.8) 9 (9.8)
Employment Status
Employed 17 (28.3) 29 (26.6) 26 (28.3) 0.04
Unemployed 13 (21.7) 24 (22.0) 13 (14.1)
Student 30 (50.0) 56 (51.4) 53 (57.6)
Smoker
Current Smoker 46 (76.7) 70 (63.6) 17 (18.7) 0.69
Non smoker/Ex-smoker 14 (23.3) 40 (36.4) 74 (81.3)
Age at first tobacco usea 16.4 (3.4) 18.5 (3.1) 18.1 (3.3) 0.34
Cigarettes per daya 11.1 (5.9) 8.9 (6.3) 6.8 (5.3) 0.36
Age at first alcohol usea 14.5 (1.8) 14.8 (1.4) 15.9 (1.4) 0.48
Years of alcohol consumptiona 8.7 (3.0) 6.7 (2.8) 6.8 (4.4) 0.32
Age at first cannabis usea 15.6 (2.0) 15.5 (1.6) 0.02
Years of cannabis consumptiona 7.7 (2.9) 6.1 (2.8) 0.56
Age at first MDMA usea 18.0 (2.9)
Years of MDMA consumptiona 5.2 (3.2)
aMean (SD).
bIncluding students.
cStandardized mean difference.
doi:10.1371/journal.pone.0027206.t001
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Table 2. Genotype distributions of the participants.
MDMA heavy MDMA light MDMA Cannabis Control p-valuea
5HTTLPR
L/L 7 (25.0) 9 (28.1) 16 (26.7) 31 (28.2) 29 (31.2) 0.121
*0.280
L/S 12 (42.9) 12 (37.5) 24 (40.0) 58 (52.7) 49 (52.7)
S/S 9 (32.1) 11 (34.4) 20 (33.3) 21 (19.1) 15 (16.1)
5HTTLPR+rs25531 (n = 259)
High (La/La) 5 (17.9) 9 (29.0) 14 (23.7) 25 (23.4) 21 (22.6) 0.478
*0.605
Medium (La/Lg+La/S) 13 (46.4) 12 (38.7) 25 (42.4) 55 (51.4) 52 (55.9)
Low (Lg/Lg+Lg/S+S/S) 10 (35.7) 10 (32.3) 20 (33.9) 27 (25.2) 20 (21.5)
rs25531 (n = 259)
A/A - - 53 (89.8) 93 (86.1) 77 (83.7) 0.568
G - - 6 (10.2) 15 (13.9) 15 (16.3)
5HT2A receptor his452tyr (n = 259)
His/His 21 (77.8) 21 (65.6) 42 (71.2) 59 (54.1) 59 (63.4) 0.598
*0.529
His/Tyr 6 (22.2) 11 (34.4) 17 (28.8) 50 (45.9) 34 (36.6)
5HT2A receptor T102C
T/T - - 9 (15.3) 25 (22.9) 17 (18.7) 0.448
T/C - - 28 (47.5) 45 (41.3) 48 (52.7)
C/C - - 22 (37.3) 39 (35.8) 26 (28.6)
BDNF val66met (n = 262)
val/val 22 (78.6) 20 (62.5) 42 (70.0) 59 (54.1) 59 (63.4) 0.109
*0.109
met 6 (21.4) 12 (37.5) 18 (30.0) 50 (45.9) 34 (36.6)
GRIN2B C2664T (n = 259)
C/C 19 (70.4) 19 (59.4) 38 (64.4) 57 (52.3) 54 (59.3) 0.288
*0.360
T 8 (29.6) 13 (40.6) 21 (35.6) 52 (47.7) 37 (40.7)
COMT val158met
val/val 12 (42.9) 9 (28.1) 21 (35.0) 26 (23.6) 27 (29.0) 0.069
*0.037
val/met 13 (46.4) 13 (40.6) 26 (43.3) 70 (63.6) 45 (48.4)
met/met 3 (10.7) 10 (31.2) 13 (21.7) 14 (12.7) 21 (22.6)
CYP2D6
Poor/Intermediate - - 9 (16.4) 14 (14.4) 13 (16.2) 0.928
Extensive/ultra-rapid - - 46 (83.6) 83 (85.6) 67 (83.8)
Genotype Combinations
5HTTLPR+COMT val158met
L+met - - 24 (40.0) 68 (61.8) 57 (61.3) 0.075
L+val/val - - 16 (26.7) 21 (19.1) 21 (22.6)
S/S+met - - 15 (25.0) 16 (14.5) 9 (9.7)
S/S+val/val - - 5 (8.3) 5 (4.5) 6 (6.5)
5HTTLPR+BDNF val66met (n = 262)
L+met - - 13 (21.7) 41 (37.6) 27 (29.0) 0.042
L+val/val - - 27 (45.0) 47 (43.1) 51 (22.6)
S/S+met - - 5 (8.3) 9 (8.3) 7 (7.5)
S/S+val/val - - 15 (25.0) 12 (11.0) 8 (8.6)
5HTTLPR+5HT2A his452Tyr (n = 259)
L+His/His - - 27 (45.8) 70 (64.2) 56 (61.5) 0.070
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light MDMA users (t = 4.1, df = 58, p,0.001), cannabis users
(t = 5.6, df = 136, p,0.0001), and non-users (t = 5.7, df = 119,
p,0.0001).
We observed a significant group x genotype interaction for the
COMT val158met (p,0.05). When the val/met genotype was
examined, heavy MDMA users with this genotype had lower
scores than light MDMA users (t = 4.7, df = 58, p,0.0001),
cannabis users (t = 5.9, df = 136, p,0.0001) or non-users (t = 6.1,
df = 119, p,0.0001) with the same genotype.
When considering the combination of the COMT val158met and
5HTTLPR genotypes, we also found an effect of the group x
genotype interaction (F = 2.7, df1 = 6, df2 = 249, p= 0.014).
MDMA users carrying the S/S+val/val genotype scored poorer
than non-users carrying the same genotype (t = 3.5, df = 9,
p= 0.01). In addition, concerning the L+met genotype, MDMA
users scored poorer than Cannabis users (t = 3.3, df = 90,
p= 0.001).
Immediate Recall
We found a main effect of group, with heavy MDMA users
having significantly lower scores than light MDMA users (t = 3.2,
df = 60, p,0.01), cannabis users (t = 4, df = 136, p,0.001), and
non-users (t = 3.7, df = 119, p,0.01).
When examining the combination of the COMT val158met and
5HTTLPR genotypes, we found a group x genotype effect (F = 2.7,
df1 = 6, DF2 = 249, p= 0.015); MDMA individuals with the S/
S+val/val genotype had significantly lower scores than non-users
carrying the same genotype (t = 4.5, df = 9, p,0.01).
Delayed recall. We found a main group effect (p,0.01), with
heavy MDMA users having significantly lower scores than
cannabis users (t = 3.9, df = 136, p,0.001), and non-users
(t = 3.2, df = 119, p,0.01). We also found a main effect of
5HT2A genotype, indicating that individuals carrying the His/Tyr
variant had significantly poorer performance than those with the
His/His genotype (t = 2.4, df = 252, p= 0.01).
The study of the interaction between the COMT val158met and
5HTTLPR genotypes showed an effect of the group x genotype
interaction (p= 0.01). Pairwise comparisons showed that MDMA
users carrying the S/S+val/val combination had significantly lower
scores than non-users (t = 4.2, df = 9, p,0.01).
Attention/Speed (SDMT)
We found no significant main effect of group on performance in
this test.
We found a significant group x 5HTTLPR genotype interaction
(F = 2.7, df1 = 6, df2 = 249, p= 0.016), with heavy MDMA users
carrying the S/S genotype performing poorer than S/S non-users
(t = 3.1, df = 33, p= 0.01).
In addition, we observed a significant group x genotype
interaction for the combination of 5HTTLPR and the COMT
val158met genotypes (F = 4.1, df1 = 6, df2 = 249, p= 0.001). Pair-
wise comparisons showed that MDMA users carrying the S/S+val/
val combination performed significantly more poorly than MDMA
L+val/val carriers (t = 3.2, df = 19, p,0.01).
Semantic Fluency
The semantic word fluency was unaffected by group or
genotypes alone. However, there was a significant effect of the
group x CYP2D6 phenotype interaction (F = 3.1, df1 = 2,
df2 = 224, p,0.05). In non-users, individuals who were Interme-
diate/Poor for the CYP2D6 performed worse than those who were
Ultra-rapid/Extensive (t = 2.8, df = 78, p,0.01). In contrast,
MDMA heavy MDMA light MDMA Cannabis Control p-valuea
L+Tyr - - 21 (20.3) 18 (16.5) 20 (22.0)
S/S - - 20 (33.9) 21 (19.3) 15 (16.5)
Results as the number of subjects (n) and percentage per genotype (%).
aThe first of both values corresponds to the comparison of ecstasy users, cannabis users, and controls. The second (with an *) corresponds to the comparison of heavy
ecstasy users, light ecstasy users, cannabis users, and controls.
doi:10.1371/journal.pone.0027206.t002
Table 2. Cont.
Table 3. Neuropsychological performance as a function of drug use status. Results are presented as mean (standard deviation).
Group Ecstasy heavy (n=28) Ecstasy light (n =32) Cannabis (n =110) Control (n = 93) p-value
CVLT
Immediate Recall 11.3 (2.5) 11.6 (2.6) 11.6 (2.5) 12.5 (2.1) 0.301
Delayed Recall 11.5 (2.3) 11.7 (2.4) 11.6 (2.6) 12.6 (2.2) 0.221
Total Recognition 14.5 (0.9) 14.2 (0.9) 14.1 (1.2) 14.4 (1.0) 0.279
Total A1–A5 50.9 (8.3) 53.5 (8.6) 52.8 (8.3) 55.8 (6.7) 0.211
ROCFT
Copy Accuracy 31.6 (3.3) 34.1 (1.9) 34.5 (2.5) 34.5 (2.2) 0.000
Immediate Recall 20.5 (5.6) 24.7 (4.5) 24.9 (5.2) 25.2 (4.9) 0.001
Delayed Recall 20.6 (5.5) 24.4 (4.4) 24.9 (5.0) 24.7 (4.9) 0.002
SDMT 55.8 (10.1) 59.2 (11.9) 59.7 (9.2) 61.6 (10.4) 0.185
Semantic Fluency 23.6 (3.5) 23.8 (5.4) 24.7 (5.6) 26.3 (6.3) 0.218
doi:10.1371/journal.pone.0027206.t003
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MDMA users with the Ultra-rapid/Extensive phenotype had
significantly lower scores than those with the same phenotype in
the non-user group (t = 2.8, df = 111, p,0.01).
Discussion
Our findings show detrimental effects of both MDMA lifetime
use and variations in candidate genes on a number of
neuropsychological measures, with particular relevance of visuo-
spatial attention and memory. With respect to dose-related effects,
we found that greater lifetime use of MDMA is negatively
correlated with performance on visuospatial memory (ROCFT)
and attention and perceptual speed (SDMT) tests. These results
were further supported by group comparisons, which showed that
heavy MDMA users (lifetime use.100 tablets) have significantly
poorer visuospatial memory than light MDMA users, cannabis
users and non-users. Importantly, we found a number of gene x
MDMA interaction effects. Results for COMT and SERT genes
showed that MDMA users carrying the COMT val/val and SERT
S/S genotypes have poorer performance on tests of visuospatial
memory and perceptual attention (ROCFT and SDMT). Delayed
recall was also modulated by a gene polymorphism in the 5HT2a
Table 4. Neuropsychological performance as a function of gene x drug use interaction.
Groups
Ecstasy heavy (n =28) Ecstasy light (n =32) Cannabis (n=110) Control (n= 93) p-value
ROCFT – copy accuracy
COMT val158met
val/val 32.2 (3.4) 33.2 (1.8) 33.5 (3.8) 35.1 (1.5) 0.020
val/met 31.1 (3.5) 34.5 (1.9) 34.7 (1.9) 34.7 (1.6)
met/met 31.7 (2.1) 34.3 (1.9) 35.1 (1.8) 33.2 (3.2)
COMT val158met and 5HTTLPR genotypes combinations
L+met 32.8 (2.8)* 34.8 (1.9) 34.2 (2.4) 0.014
L+val/val 33.2 (2.3)* 33.0 (4.1) 34.9 (1.7)
S/S+met 33.6 (3.2)* 34.9(1.7) 34.6 (1.4)
S/S+val/val 30.8 (3.7)* 35.6 (0.9) 35.8 (0.4)
ROCFT – immediate recall
COMT val158met and 5HTTLPR genotypes combinations
L+met 23.0 (5.4)* 24.2 (5.3) 24.6 (5.2) 0.015
L+val/val 22.6 (5.4)* 26.5 (5.0) 26.9 (4.2)
S/S+met 24.2 (5.2)* 26.4 (4.3) 22.2 (3.7)
S/S+val/val 17.5 (4.1)* 23.6 (5.0) 29.4 (1.6)
ROCFT – delayed recall
COMT val158met and 5HTTLPR genotypes combinations
L+met 22.6 (5.3)* 24.2 (5.3) 24.3 (5.1) 0.011
L+val/val 22.6 (5.4)* 25.8 (4.8) 26.4 (4.1)
S/S+met 24.5 (4. 9)* 26.6 (4.1) 21.1 (3.5)
S/S+val/val 18.0 (3.8)* 24.9 (4.2) 28.6 (2.5)
SDMT
5HTTLPR
L/L 56.7 (9.2) 57.2 (7.5) 57.1 (9.5) 62.1 (11.1) 0.016
L/S 59.2 (10.6) 62.8 (14.1) 60.0 (8.4) 59.7 (9.1)
S/S 50.4 (8.6) 56.7 (12.1) 62.6 (10.2) 66.9 (11.9)
COMT val158met and 5HTTLPR genotypes combinations
L+met 58.5 (10.6)* 58.4 (9.0) 60.3 (10.7) 0.001
L+val/val 60.9 (11.5)* 61.0 (8.2) 61.5 (7.3)
S/S+met 57.5 (9.6)* 63.9 (10.1) 62.7 (6.0)
S/S+val/val 43.2 (7.1)* 58.4 (10.8) 73.2 (16.0)
Semantic Fluency
CYP2D6 Phenotype
Intermediate/Poor 21.7 (4.7)* 25.7 (6.0) 22.5 (6.6) 0.047
Ultra-rapid/Extensive 24.0 (4.7)* 25.0 (5.6) 27.5 (5.9)
*Refers to the MDMA group irrespective of the lifetime consumption (n = 60).
Results are presented as mean (standard deviation).
doi:10.1371/journal.pone.0027206.t004
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receptor, such that Tyr carriers had poorer performance
irrespective of drug use. Finally, we found an interaction between
MDMA use and CYP2D6 extra-high metabolic activity phenotype
and lower performance on verbal fluency.
The main MDMA dose-related findings and MDMA x gene
interactions were found in the ROCFT. This is a complex task
involving visuospatial attention and planning/organization skills
during the copy, and planning and episodic memory skills during
immediate and delayed recall [42]. Copy performance is
associated with dorsolateral prefrontal cortex (DLPFC) and
parietal cortex functioning [43], whereas immediate and delayed
recall are associated with the functioning of the DLPFC [44] and
the hippocampus [45]. Therefore, our findings point to a
substantial impact of MDMA lifetime amount of use on fronto-
parietal and fronto-temporal systems supporting attentional and
memory functions, in agreement with previous neuropsychological
and neuroimaging findings [46–48]. The fact that the larger dose-
related correlations are found for the Copy index indicates that
MDMA cumulative use may have greater detrimental effects on
visuospatial attention and organization skills than on recall per se;
this is consistent with the finding that MDMA use is also negatively
associated with SDMT-indexed perceptual attention, and with
decreased gray matter volumes and SERT availability in posterior
brain cortices [48].
The association between MDMA use and perceptual attention
and visual memory/organization skills seems to be modulated by
COMT and SERT genotypes. Our results consistently showed that
MDMA users carrying the COMT val/val and SERT S/S genotypes
perform significantly more poorly on ROCFT Copy, Immediate
and Delayed Recall, and on SDMT, such that there was consistency
between gene x drug effects on different probes involving perceptual
attention and visuospatial planning/memory skills. These results fit
with evidence showing that the COMT gene is significantly
associated with visuospatial planning ability –gene-carriers with
high enzymatic activity display poorer performance [49] and
reduced DLPFC and parietal activation during planning tasks [50].
They are also in agreement with neuropsychological outcomes in
individuals with microdeletion of chromosome 22q11.2 –in which
the COMT is one of the genes in the deleted region– displaying
robust deficits in the ROCFT [43]. There is also evidence of the
influence of the SERT genotype on visuospatial attention/planning
performance indexed by a Mental Rotation task after tryptophan
depletion –which mimics MDMA-induced serotonin reductions
[51]. Furthermore, MDMA chronic use is robustly associated with
loss of SERT availability in occipital, hippocampal and parietal
regions [48], all networks involved in perceptual/attentional
processing and memory. Overall, our results are suggestive of the
notion that heavy MDMA use and COMT val/val and SERT S/S
genotypes interact to produce greater detrimental effects on
perceptual attention and planning/organization, ultimately affect-
ing visuospatial memory skills. However, these results would need
follow-up in larger samples, and they need to be interpreted with
caution considering that the role of the COMT gene on cognition
and brain functioning is still controversial [52,53]. In the case of
delayed recall, performance was further modulated by a 5HT2a
gene polymorphism, such that Tyr carriers have poorer perfor-
mance irrespective of drug use; this is in agreement with previous
observations on the association between this genotype and the
consolidation process of episodic memory [54].
In agreement with our initial assumptions, MDMA users with
CYP2D6 high metabolic activity phenotypes performed more
poorly on the semantic fluency test. These results are in agreement
with recent findings about the link between higher CYP2D6 activity
and impaired executive performance, including semantic fluency, in
methamphetamine users [55]. In this case, we extend their findings
by showing specific effects of the Ultra-rapid/Extensive phenotype
on executive performance in MDMA users, a drug-using group in
which greater cognitive dysfunction was expected based on specific
pharmacodynamic mechanisms [56]. Furthermore, fluency is one of
the executive skills more consistently impaired in MDMA users
[57], conferring clinical significance to this gene x drug interaction
effect. This finding supports the proposal that CYP2D6 polymor-
phisms may modulate MDMA-induced neurotoxic effects [17] and
subsequent decrements in executive performance. More research
including additional executive phenotypes and larger sample sizes
are warranted to further substantiate these promising findings.
Three other polymorphisms –the BDNF val/met, the 5HT2a T102C,
and the GRIN2B C2664T– were explored but failed to show
significant results in relation to cognitive performance. Nonetheless,
the GRIN2B genotype showed a trend to significance in relation to
verbal memory (T allele carriers recalling more words), raising the
possibility that effects of these genes on cognition may emerge in
larger samples sizes.
In conclusion, this study reliably demonstrates dose-related
effects of MDMA use on visual attention, organization and
memory. In addition, we show an interaction between MDMA use
and different gene polymorphisms in determining poorer perfor-
mance of MDMA users in tests of visual attention and memory
(COMT and SERT genes) and verbal fluency (CYP2D6). Strengths
from the study include the successful recruitment of a large
number of non-treatment seeking MDMA users who self-report an
adequate academic/ professional and social functioning, thus
avoiding socio-demographic confounders and approximating
research to the reality of MDMA use beyond clinical settings;
the carefully conducted medical and psychiatric explorations to
discard potential confounders related to physical illness or
psychopathology; and the use of well-validated neuropsychological
measures taxing key cognitive domains related to MDMA use.
Limitations include the relatively small sample size for a genetic
study –especially when combining some of the rare genotypes, and
the elevated number of statistical comparisons, which may have
inflated the risk of Type I error. Nonetheless, we should note that
our drugs x gene interaction findings are in agreement with initial
assumptions, biologically plausible and overly consistent with
previous literature, and consistent across independent but
conceptually related neuropsychological probes and indices.
Therefore, although these results would need to be further
explored and replicated, we arguably reckon that the probability
that they stem from false positive effects is low.
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